Alkermes plc.

Alkermes PLC.

Drug Manufacturers - Specialty & Generic • Healthcare • Dublin, Ireland • ALKS (NMS)

Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. It has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical product candidates in development for neurological disorders. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ARISTADA INITIO for the treatment of schizophrenia in adults; VIVITROL for the treatment of alcohol and prevention of opioid dependence; and LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder. The company also offers proprietary technology platforms to third parties to enable them to develop, commercialize, and manufacture products. It has collaboration agreements primarily with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.

Stock Performance (90 Days)

Data through Dec 24, 2025
Price updates on page refresh. Intraday quotes available during market hours (9:30 AM - 4:00 PM EST).

Layoff History

No layoff events recorded for this company.

Recent News

VIRGINIA RETIREMENT SYSTEMS ET Al Invests $27.04 Million in Alkermes plc $ALKS - MarketBeat
MarketBeat • Dec 31
Brain disorder drug maker brings its latest update to J.P. Morgan stage - Stock Titan
Stock Titan • Dec 30
Why Analysts are Rating Alkermes (ALKS) a Buy - Yahoo Finance
Yahoo Finance • Dec 22
Alkermes plc Reports Third Quarter 2025 Financial Results - PR Newswire
PR Newswire • Oct 28
Alkermes falls after mid-stage trial data for sleep therapy - Seeking Alpha
Seeking Alpha • Nov 12

Other Drug Manufacturers - Specialty & Generic Companies

View All →
Elanco Animal Health Inc logo Elanco Animal Health Inc.
1 layoff tracked
$11.23B market cap
Zoetis Inc. logo Zoetis Inc.
$55.83B market cap
Galderma Group AG/ADR logo Galderma Group AG
$49.28B market cap
TAKEDA PHARMACEUTICAL CO LTD logo Takeda Pharmaceutical Co. Ltd.
$47.02B market cap
Haleon plc logo Haleon PLC
$44.93B market cap
TEVA PHARMACEUTICAL INDUSTRIES LTD logo TEVA Pharmaceutical Industries Ltd.
$32.82B market cap

Frequently Asked Questions

Has Alkermes plc. had layoffs?
No layoff events have been recorded for Alkermes plc. in our database. This could mean the company has not conducted significant layoffs, or any layoffs have not been publicly reported.
How many employees does Alkermes plc. have?
Alkermes plc. has approximately 1,800 employees.
What industry is Alkermes plc. in?
Alkermes plc. operates in the Drug Manufacturers - Specialty & Generic industry, within the Healthcare sector.
Is Alkermes plc. a publicly traded company?
Yes, Alkermes plc. is publicly traded under the ticker symbol ALKS on the NMS. The company has a market capitalization of approximately $4.71 billion.
Where is Alkermes plc. headquartered?
Alkermes plc. is headquartered in Dublin, Ireland.

Disclaimer

Data aggregated from public sources including WARN notices, SEC filings, press releases, and market data. While we strive for accuracy, information is provided "as-is" for informational purposes only. Always verify critical information with official company sources.

This information does not constitute investment, financial, legal, or career advice. See our Terms of Service, Privacy Policy, and About page for more information.

Found an error? Report it here.